Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Over a 12-month period, patients showed sustained improvements in disease progression through valbenazine, regardless of concomitant antipsychotic treatment.

Valbenazine Shows Sustained Treatment Effect on Huntington’s Chorea in KINECT-HD2 Open-Label Data

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 4, 2024. 

NeurologyLive® Friday 5 — October 4, 2024

Amifampridine enhances neuromuscular transmission and relieves muscle weakness, showing promise for Lambert-Eaton myasthenic syndrome and other neuromuscular junction disorders.

Unwinding Histone Deacetylase Inhibitors: Givinostat in Duchenne Muscular Dystrophy

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Daniel Ontaneda, MD, PhD. [LISTEN TIME: 27 minutes]

Episode 125: Understanding Major Changes to New McDonald Criteria for Multiple Sclerosis

The Total Posterior Spine System offers a promising alternative to spinal fusion, preserving mobility and reducing strain on adjacent spinal levels in patients with spondylolisthesis and spinal stenosis.

Promising Outcomes for Spinal Stenosis and Spondylolisthesis: An Alternative to Spinal Fusion

Advanced Heart Failure Physician-Scientist at the University of Minnesota.

As part of our monthly clinician spotlight, NeurologyLive® highlighted neuromuscular-associated cardiomyopathy expert Forum Kamdar, MD, PhD, FACC, FHFSA, an advanced heart failure physician-scientist at the University of Minnesota.

NeurologyLive® Clinician of the Month Spotlight: Forum Kamdar, MD, PhD, FACC, FHFSA

, has been with the team since October 2019. Follow him on Twitter 

Tim Miller, MD, director of functional neurosurgery at the Marcus Neuroscience Institute, Baptist Health, provided commentary on the use of HIFU as a non-invasive treatment for patients with essential tremor and specific types of Parkinson disease.

Exploring the Treatment Possibilities and Functionality of High Intensity Focused Ultrasound

Videos

The chief research officer of the Muscular Dystrophy Association talked about what is to be expected at the 2025 MDA Conference, held March 16-19, in Dallas, Texas. [WATCH TIME: 5 minutes]

A Melting Pot of Strategies and Collaboration at the 2025 MDA Conference: Sharon Hesterlee, PhD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

YouTube

Spotlight

ECTRIMS 2024

MDS 2024

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

Rapid Readout: Clinical Updates in Multiple Sclerosis From CMSC 2020

Consortium of Multiple Sclerosis Centers Annual Meeting (CMSC)

The Multidisciplinary Theme of CMSC 2020

Progressive MS: The 2020 Whitaker Lecture

Ocrelizumab Compared to Glatiramer Acetate and Dimethyl Fumarate for MS

Post Hoc Analysis: Phase 3 ASCLEPIOS I and II Trials in Relapsing MS

Primary Results From the ENSEMBLE PLUS Study

Post Hoc Analysis: Phase 3 EXPAND Trial in Secondary Progressive MS

Open-Label Extension: Phase 3 OPERA I and II Trials in Relapsing MS

CMSC Data Release: Abstract DXT58 and MS Risk Reduction

Open-Label Extension: BTKI in Relapsing MS Over 108 Weeks

Clinical

EMD-22-NRD0193 - /clinical/multiple-sclerosis

The News Network video series features a variety of clinicians providing updates on the major data and paradigm-affecting updates from societal meetings and conferences focused on patients with neurologic diseases.